Stock ELUT ELUTIA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Elutia Inc.

Equities

ELUT

US05479K1060

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
4.5 USD -3.43% Intraday chart for Elutia Inc. +2.74% +108.33%
Jul. 01 Elutia Inc.(NasdaqCM:ELUT) dropped from Russell Microcap Growth Index CI
Jul. 01 Elutia Inc.(NasdaqCM:ELUT) added to Russell Microcap Value Index CI

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
AQ
Elutia Announces $13.26 Million Registered Direct Offering
AQ
Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
AQ
Elutia : Q1 2024 Financial Results Presentation
PU
Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance
AQ
Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
AQ
Elutia Planet MicroCap Showcase: VEGAS 2024 Presentation
PU
Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
AQ
Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
AQ
Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
AQ
Elutia's CanGarooRM: Pioneering Drug-Eluting Biologic for Secure Medical Implants
AQ
Elutia Regains Compliance with Nasdaq Listing Requirements
AQ
Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance
AQ
Elutia : The Wall Street Transcript
PU
Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results
AQ
Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million
AQ
Elutia to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
AQ
Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices
AQ
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
AQ
Aziyo Biologics : 2Q 2023 Financial Results Presentation
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ELUT Stock
  4. News Elutia Inc.
  5. Press Releases